Bacterial Conjunctivitis Drugs Market By Drug Class ( Fluoroquinolones, Aminoglycosides, Macrolides ), Industry Trends, Estimation & Forecast, 2017 - 2025

Bacterial Conjunctivitis Drugs Market is expected to generate $435 million by the end of 2025.

Market Overview:

The global bacterial conjunctivitis drugs market has experienced sluggish growth in past few years and it is expected that the growth would decline in years to come. Moreover, patents for key drugs such as Moxeza, Besivance, Vigamox, and Zymaxid are on the verge of expiring which may cause decline in the revenue generation in near future. According to JAMA (Journal of the American Medical Association), half of the conjunctivitis patients in the U.S. are suffering from bacterial conjunctivitis, resulting in an increase in demand for effective drugs to treat the same. Patient assistance programs offered by drug suppliers and introduction of multi-drug resistant variants are also expected to spur the market growth. In addition to expiration of patents for drugs, tendency of self-medication among patients may also restrict the market growth. Asia-Pacific offers various opportunities for drug manufacturers due to increase in disposable income and support offered by governments for conjunctivitis drugs. The report provides detailed qualitative and quantitative analysis of the global bacterial conjunctivitis drugs market. Market size and forecast in terms of value has been provided for the period - (2017 - 2025), for the segments namely drug class in each of the major regions of the world.

Bacterial Conjunctivitis Drugs Market Segmentation

By Drug Class • Fluoroquinolones • Aminoglycosides • Macrolides • Others By Geography • North America o U.S. o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o Japan o China o India o Rest of Asia-Pacific • Rest of the World o Middle East o Latin America o Africa

CHAPTER 1. INTRODUCTION 1.1. RESEARCH METHODOLOGY 1.1.1. ERC desk research 1.1.2. ERC data synthesis 1.1.3. Data validation and market feedback 1.1.4. ERC data sources CHAPTER 2. BACTERIAL CONJUNCTIVITIS DRUGS MARKET OVERVIEW 2.1. BACTERIAL CONJUNCTIVITIS DRUGS MARKET INTRODUCTION 2.2. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025 2.2.1. Global Bacterial Conjunctivitis Drugs Market Revenue (Million USD) and Growth Rate (%), (2017-2025) CHAPTER 3. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET BY DRUG CLASS, 2017-2025 3.1. FLUOROQUINOLONES 3.2. AMINOGLYCOSIDES 3.3. MACROLIDES 3.4. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY DRUG CLASS, 2017-2025 3.4.1. Global Bacterial Conjunctivitis Drugs Market Revenue (Million USD) and Share (%) By Drug Class, 2017-2025 3.4.2. Fluoroquinolones Market Revenue and Growth Rate, 2017-2025 3.4.3. Aminoglycosides Market Revenue and Growth Rate, 2017-2025 3.4.4. Macrolides Market Revenue and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for other drug class segment. CHAPTER 4. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET BY REGION, 2017-2025 4.1. NORTH AMERICA 4.1.1. U.S. 4.1.2. Canada 4.1.3. Mexico 4.2. EUROPE 4.2.1. U.K. 4.2.2. France 4.2.3. Germany 4.2.4. Italy 4.2.5. Spain 4.2.6. Rest of Europe 4.3. ASIA PACIFIC 4.3.1. China 4.3.2. Japan 4.3.3. India 4.3.4. Korea 4.3.5. Rest of APAC 4.4. SOUTH AMERICA 4.4.1. Brazil 4.4.2. Rest of South America 4.5. REST OF THE WORLD 4.5.1. Middle East 4.5.2. Africa 4.6. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY REGION, 2017-2025 4.6.1. Global Bacterial Conjunctivitis Drugs Market Revenue (Million USD) and Share (%) By Region, 2017-2025 4.6.2. North America Market Revenue and Growth Rate, 2017-2025 4.6.3. Europe Market Revenue and Growth Rate, 2017-2025 4.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025 4.6.5. South America Market Revenue and Growth Rate, 2017-2025 4.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025 CHAPTER 5. MARKET DETERMINANTS 5.1. MARKET DRIVERS 5.2. MARKET RESTRAINTS 5.3. MARKET OPPORTUNITIES 5.4. MARKET DETERMINANTS RADAR CHART CHAPTER 6. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET COMPETITION BY SERVICE PROVIDERS 6.1. GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025) 6.1.1. Global Bacterial Conjunctivitis Drugs Revenue (Million USD) and Share (%) by Service Providers (2017-2025) 6.2. BACTERIAL CONJUNCTIVITIS DRUGS MARKET COMPETITIVE SITUATION AND TRENDS 6.2.1. Bacterial Conjunctivitis Drugs Market Share (%) of Top 3 Service Providers 6.2.2. Bacterial Conjunctivitis Drugs Market Share (%) of Top 5 Service Providers CHAPTER 7. COMPANY PROFILES 7.1. ACTAVIS PLC. 7.1.1. Business Overview 7.1.2. Company Basic Information 7.1.3. Bacterial Conjunctivitis Drugs Product Details 7.1.4. Actavis Plc. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.2. BAYER AG 7.2.1. Business Overview 7.2.2. Company Basic Information 7.2.3. Bacterial Conjunctivitis Drugs Product Details 7.2.4. Bayer AG Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.3. AKORN, INC. 7.3.1. Business Overview 7.3.2. Company Basic Information 7.3.3. Bacterial Conjunctivitis Drugs Product Details 7.3.4. Akorn, Inc. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.4. F.HOFFMAN LA-ROCHE LTD. 7.4.1. Business Overview 7.4.2. Company Basic Information 7.4.3. Bacterial Conjunctivitis Drugs Product Details 7.4.4. F.Hoffman La-Roche Ltd. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.5. MERCK & CO., INC. 7.5.1. Business Overview 7.5.2. Company Basic Information 7.5.3. Bacterial Conjunctivitis Drugs Product Details 7.5.4. Merck & Co., Inc. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.6. NOVARTIS AG 7.6.1. Business Overview 7.6.2. Company Basic Information 7.6.3. Bacterial Conjunctivitis Drugs Product Details 7.6.4. Novartis AG Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.7. INSITE VISION INCORPORATED 7.7.1. Business Overview 7.7.2. Company Basic Information 7.7.3. Bacterial Conjunctivitis Drugs Product Details 7.7.4. InSite Vision Incorporated Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.8. PERRIGO COMPANY PLC. 7.8.1. Business Overview 7.8.2. Company Basic Information 7.8.3. Bacterial Conjunctivitis Drugs Product Details 7.8.4. Perrigo Company Plc. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.9. SANTEN PHARMACEUTICAL CO., LTD. 7.9.1. Business Overview 7.9.2. Company Basic Information 7.9.3. Bacterial Conjunctivitis Drugs Product Details 7.9.4. Santen Pharmaceutical Co., Ltd. Bacterial Conjunctivitis Drugs Revenue and Gross Margin 7.10. PFIZER, INC. 7.10.1. Business Overview 7.10.2. Company Basic Information 7.10.3. Bacterial Conjunctivitis Drugs Product Details 7.10.4. Pfizer, Inc. Bacterial Conjunctivitis Drugs Revenue and Gross Margin CHAPTER 8. BACTERIAL CONJUNCTIVITIS DRUGS MARKET VALUE CHAIN ANALYSIS 8.1. BACTERIAL CONJUNCTIVITIS DRUGS INDUSTRIAL CHAIN ANALYSIS 8.2. CONSUMER ANALYSIS 8.2.1. Consumer 1 8.2.2. Consumer 2 8.2.3. Consumer 3 8.2.4. Consumer 4

• Actavis Plc.
• Bayer AG
• Akorn, Inc.
• F.Hoffman La-Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• InSite Vision Incorporated
• Perrigo Company Plc.
• Santen Pharmaceutical Co., Ltd.
• Pfizer, Inc.

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS